Featured Research

from universities, journals, and other organizations

Pathology Reports Acceptable For Determining ER Status In Breast Cancer Trials

Date:
January 30, 2008
Source:
Journal of the National Cancer Institute
Summary:
Pathology reports offer a fairly accurate alternative to repeated testing in a central laboratory for determining estrogen receptor status in large epidemiologic studies of women with breast cancer. When conducting epidemiologic studies of breast cancer patients, researchers often use pathology reports to obtain estrogen receptor status instead of testing them again in a central laboratory, which can be impractical.

Pathology reports offer a fairly accurate alternative to repeated testing in a central laboratory for determining estrogen receptor status in large epidemiologic studies of women with breast cancer.

When conducting epidemiologic studies of breast cancer patients, researchers often use pathology reports to obtain estrogen receptor status instead of testing them again in a central laboratory, which can be impractical.

But it was unknown whether these original pathology reports were accurate or not, and misclassification of estrogen receptor status could have a serious impact on the results of a study.

Laura Collins, M.D., of Beth Israel Deaconess Medical Center in Boston and colleagues assessed the reliability of estrogen receptor results from pathology reports by comparing them with immunohistochemical tests that they had performed by a central laboratory.

The pathology reports and the later tests were the same for 1,615 of the 1,851 samples (87.3 percent). The authors concluded that there was a high rate of agreement between the pathology reports and the central laboratory tests.

"Our findings, therefore, indicate that using [estrogen receptor] assay results from pathology reports is a reasonable alternative to using central laboratory testing to obtain [estrogen receptor] results in large, population-based studies of women with breast cancer," the authors write.

This research was recently published in the Journal of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Pathology Reports Acceptable For Determining ER Status In Breast Cancer Trials." ScienceDaily. ScienceDaily, 30 January 2008. <www.sciencedaily.com/releases/2008/01/080129200314.htm>.
Journal of the National Cancer Institute. (2008, January 30). Pathology Reports Acceptable For Determining ER Status In Breast Cancer Trials. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/01/080129200314.htm
Journal of the National Cancer Institute. "Pathology Reports Acceptable For Determining ER Status In Breast Cancer Trials." ScienceDaily. www.sciencedaily.com/releases/2008/01/080129200314.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins